organophosphate paraquat
TRANSCRIPT
-
8/16/2019 Organophosphate Paraquat
1/38
19 !"#$%! 2556
'($)*$++, *-$*$+./0 +, 12$+34-
Organophosphate &56 Paraquat
#3.78+!9: 78; 5
&3(9? 8+6@A$10 $#B, C #8;(" D 3 2$E$F$B"'?
-
8/16/2019 Organophosphate Paraquat
2/38
• Insecticide
• Organophosphates
• Carbamates
• Organochlorines
• Pyrethrins
• Rodenticide
• Coumarin
• Thallium
• Zinc phosphine
• Herbicide
• Paraquat
• Glyphosate
Pesticides
-
8/16/2019 Organophosphate Paraquat
3/38
• Parathion
• Malathion
• Fenthion
• Dimethoate
• Monocrotophos
• Methamidophos
Organophosphate
-
8/16/2019 Organophosphate Paraquat
4/38
LD50
!" #$%&'( ) !" #$*&+,- & LD50(mg/kg)
Parathion ./012$3,4&+&5'6 4-13
Monocrotophos $7.82+13.'/$% 8-23
Methamidophos 4&+&.*+.'3159$+: 5$/ 5 19-21
Malathion '&0&/$%,'&0&6;$*8: 1000
Dimethoate 5265'6 215
-
8/16/2019 Organophosphate Paraquat
5/38
• Inhalation
: unlikely at ordinary temperatures, low volatility
: sprays or dusts
• Skin/eye contact
: rapidly absorbed through intact skin and eyes,contributing to systemic toxicity
• Ingestion
: acute toxicity and rapidly fatal systemicpoisoning
Route of exposure
-
8/16/2019 Organophosphate Paraquat
6/38
• Inhibit enzyme acetylcholinesterase (AchE)
• Blockade of AchE lead to excessive acetylcholine at• Muscarinic receptors
• Nicotinic receptors
• Central nervous system (CNS)
Mechanism of toxicity
-
8/16/2019 Organophosphate Paraquat
7/38
• Muscarinic Cholinergic
• Parasympathetic nervous system and Sweat gland • Excessive Ach lead to
• Sweating (7H)I DFFF*!$*)
• Lacrimation (#C A$G$.H5)
• Salivation (#C A$5$9.H5) • Bronchorrhea (24 D)%,/H5, D)J#H5F/5!) • Bronchospasm (H5F/5!G"1) • Nausea&Vomiting (%5I D#.20 F$7@"9#) • Diarrhea ((0 F)72"9)
• Urination (8K22$'6+$/) • Miosis (+L!M$#G$75N*) • Bradycardia (H, 'J@7G0 #B0 $)
Mechanism of toxicity
SLUDGE
DUMBELS
Salivation, Lacrimation, Urination, Diarrhea,
Gastrointestinal distress , Emesis
Diarrhea, Urination, Miosis,Bronchospasam, Bronchorrhea, Bradaycardia,
Emesis, Lacrimation, Salivation
-
8/16/2019 Organophosphate Paraquat
8/38
• Nicotinic Cholinergic
• Muscle Motor End-plate and Sympathetic nervoussystem
• Excessive Ach lead to • Fasciculation (*50 $!7#I C F3+4 C ')
• Weakness (*50 $!7#I C FFMF#&+)) • Paralysis (F, !3$G) • Tachycardia (B"3@+7G0 #7+N')
• Hypertension (%'$!/, #O5H4G2L))
• Adrenal Stimulation(*+6G> 0 #*$+(A$)$#EF)GMF!H!'*.G)
Mechanism of toxicity
-
8/16/2019 Organophosphate Paraquat
9/38
• Central Nervous System (CNS)
• Muscle Motor End-plate and Sympathetic nervoussystem
• Excessive Ach lead to • Seizure (B, *)
• Coma (H!/2G4) • Respiratory depression (*/*$+H$9J@)
Mechanism of toxicity
-
8/16/2019 Organophosphate Paraquat
10/38
• Onset
• Chemical warfare • Sarin = 5 mins
• Agriculture chemical• 15 mins – 24 hrs
• Mostly within 8 hrs
Mechanism of toxicity
-
8/16/2019 Organophosphate Paraquat
11/38
$&*&+
-
8/16/2019 Organophosphate Paraquat
12/38
• !, *7*4/G$!H5, )F$*$+34-7T"9135, #@$* Organophosphate 1-3', # J#UL 0 8V'9(" D!"P$'6 Cholinergic Crisis +>#&+)
• !"F$*$+FMF#&+)EF)*50 $!7#I C F1+47'SJ1H#0 $&56:"+-6(" D%'1%>!/0 '9720 #
8+62$(2!F) 7BM# 9, *%4 C '.!M ./0 5I!G$.!MEW C # *5F*G$.!M ./0 7+"9*'M$ “Bulbar Palsy” • 78Q#2$7HG>(" D(A$JH0 UL 0 8V'9H9M$7%+I DF)BM'9H$9J@.!M ./0 (Weaning of
respirator) (A$JH0 G0 F)3W D)7%+I DF)BM'9H$9J@#$#EW C # 1-3 2,8/$H?
• .!M!"*$++, *-$(" D@A$73$6 9$*5> M! oxime .!M(A$JH0 /"EW C # *$++, *-$&118+6%, 18+6%F)O/97T3$6*$+JB07%+I DF)BM'9H$9J@78Q#24 D)(" D2A$%, X(" D2>/
Intermediate Syndrome
-
8/16/2019 Organophosphate Paraquat
13/38
• Biomarker
1.Biomarker of exposure
1.1 Acetylcholinesterase (AchE) in RBC
1.2 Butyrylcholinesterase (BChE) in Plasma
2.Biomarker of effect
2.1 Electromyogram 78Q#*$+G+'@%5I D#.RRY$EF)*50 $!7#I C F O/9@6G+'@31 Spontaneous fasciculation
Laboratory
-
8/16/2019 Organophosphate Paraquat
14/38
+72( >?$=*&+6@ &=&3 cholinesterase 6A #020= - C " D
,F&'+G3
-
8/16/2019 Organophosphate Paraquat
15/38
• E0 F3W)+6', )J#*$+G+'@
• .!M2$!$+ZJB0 G4/G$!/L*$+/A$7#4#EF)O+% O/97T3$6BM')R[ \#G, 'EF)O+%./0
• P$'61$)F9M$)H+IF9$1$)B#4/ 7BM# P$'6]"/@$* hemoglobinopathy H+IF 9$ Chloroquine (A$JH0 +6/, 1*$+(A$)$#EF) AchE 5/5)./0
• *$+(A$)$#EF) AchE J#7!N/75IF/&/)J#P$'68*G4!"*$+&*'M)G, 'J#&GM56', #./0 8+6!$S+0 F956 10
• *$+7*N1G, 'F9M$)75IF/G0 F)JB0H5F/(" D!" D EDTA H+IF Heparin 7(M$#, C # H$*JB0H5F/(" D!" NaF @6(A$JH0 7*4/U5U4/35$/GD A$*'M$%'$!78Q#@+4)./0
Laboratory
-
8/16/2019 Organophosphate Paraquat
16/38
• Supportive treatment
• Primary assessment
• Airwar –Breathing–Circulation assessment • Oxygen therapy
• Semiprone position • Endotracheal intubation
• Secretion removal • Inadequate breathing • Shock
• Intravenous fluid resuscitation
• Observe seizure (Benzodiazepine)
• EKG 12 lead (Arrhythmia, QTc Prolongation)
Treatment
-
8/16/2019 Organophosphate Paraquat
17/38
• Specific treatment
• Decontamination • Remove clothing
• Cleansing
• GI Decontamination
• Do not induce vomiting ! Aspiration Pneumonitis
• Gastric lavage ! Must be within 1 hr
• Activated charcoal! Should be within 1 hr
• Antidote! Atropine , Pralidoxime (2-PAM)
• Control seizure! Diazepam
Treatment
-
8/16/2019 Organophosphate Paraquat
18/38
• FF*^(=4 _ 78Q#9$G0 $#7T3$6^(=4 _ Muscarinic cholinergic 7(M$#, C #
• E0 F1M)B" C • UL 0 (" D!"F$*$+&2/)EF) Muscarinic !$*@#F$@78Q#F,#G+$9GMFUL 0 8V'9
(DUMBELS, SLUDGE)
• 78Y$H!$9 • 5/24 D)%, /H5, D)J#($)7/4#H$9J@ 5A$.20 &56U4'H#, )
• &*0 P$'6H, 'J@7G0 #B0 $&56(A$JH0 +L!M$#G$E9$9G, '
• E#$/9$ :• Loading dose 1.8 mg IV &50 '8+67!4#]C A$J# 3-5 #$(" 8+, 1E#$/78Q#7(M$
G, '@#*'M$@6ZW)78Y$H!$9 (72!H6J#H5F/5!&H0 ) , PR > 80 bpm , SBP >80 mmHg)
• Maintenance dose JH0 ./0 78Q#%+, C )` H+IF IV drip (10-20% EF) loading doseGMFB, D'O!)) &56%'+G4/G$!(>* 15 #$("@#F$*$+%)G, '
Atropine
-
8/16/2019 Organophosphate Paraquat
19/38
• 9$*5> M! Oxime (A$H#0 $(" D reactivate 7FN#.]!? AchE J#8+67(:.(9!"B#4/7/"9'%IF Pralidoxime H+IF 2-PAM
• E0 F1M)B" C
• UL 0 (" D!"F$*$+&2/)EF)P$'678Q#34-@$* Organophosphate ( .!M#A$JH0 JB0 J#
P$'678Q#34-@$* Carbamate)
• 78Y$H!$9
• Reactivate 7FN#.]!? AchE JH0 *5, 1!$(A$)$#./0 F"*%+, C)O/98+67!4#@$*F$*$+&2/)($) Muscarinic &56 Nicotinic O/9#A$JH02, )7*GF$*$+ Fasciculation &56 Muscle Weakness 78Q#H5,*
• E#$/9$ :• Loading dose 1,000-2,000 mg IV in 10 mins • Maintenance dose 1,000 mg/hr H+IF 8-10 mg/kg/hr IV drip • %'+JH0 9$GMF7#I DF) @#R[ \#@$*P$'678Q#34-7T"9135, #.8&50 ' 12-24 B, D'O!)
Pralidoxime (2-PAM)
-
8/16/2019 Organophosphate Paraquat
20/38
• 78Q#9$2A$%, X(" D+, *-$F$*$+($)2!F) 7BM# B, * 2, 12# P$'6H9>/H$9J@]W D)7*4/@$**$+*/:L#9? %'1%>!*$+H$9J@J#2!F) 78Q#G0 #
• E0 F1M)B" C • %'1%>!P$'6B, *
• 5/F$*$+*+62, 1*+62M$9 (Anxiety, Agitation, Restless)
• 78Y$H!$9 • UL 0 8V'9H9>/B, *J#*+S"(" DB, *H+IF UL 0 8V'9H9>/3, *./0 J#*+S"(" D*+62, 1*+62M$9
• E#$/9$ :• 10-20 mg IV
Diazepam
-
8/16/2019 Organophosphate Paraquat
21/38
'($)*$+/L&5+, *-$• Flow chart.docx
• Standing order.docx
http://localhost/var/www/apps/conversion/tmp/scratch_5///ppt/slides/Standing%20order.docxhttp://localhost/var/www/apps/conversion/tmp/scratch_5///ppt/slides/Standing%20order.docxhttp://localhost/var/www/apps/conversion/tmp/scratch_5///ppt/slides/Flow%20chart.docxhttp://localhost/var/www/apps/conversion/tmp/scratch_5///ppt/slides/Flow%20chart.docx
-
8/16/2019 Organophosphate Paraquat
22/38
• 78Q#2$+*A$@, /:, G+L3IBJ#*5> M! Dipyridil compound
• !"%>S2!1, G4(" D/"*'M$2$+B#4/FI D#` %IF FF*^(=4 _ 7+N' !"8+624(=4P$32L) /, )#, C #@W)78Q#2$+*A$@, /:, G+L3IB(" D#49!JB0 !$*(" D2>/J#8+67(:.(9
• !"5, *-S678Q#2"#C A$7)4#7E0 ! !"*54 D#T># 25$9G, '(" DF>SHPL!4 300°c 565$9 ./0 /" J##C A$ %)(#J#P$'6(" D78Q#*+/ 72IDF!^(=4 _ 7+N'7!I DFF9L M J#/4#H+IFJ##C A$ (" D%'$!7E0 !E0 #2L)2$!$+Z*,/*+MF#O5H6./0
Paraquat
-
8/16/2019 Organophosphate Paraquat
23/38
• J#!#>-9? *$+*4#3$+$%'F((20%) 73"9) 10-15 cc (A$JH0 72"9B"'4G./0
LD50
!" #$%&'( ) !" #$*&+,- & LD50(mg/kg)
Paraquat *+( '';$*.83 20-50
-
8/16/2019 Organophosphate Paraquat
24/38
• Inhalation
: no volatility , spray droplets are too large to beinhaled into the lungs
: occasionally cause of nausea or headaches
• Skin/eye contact
: intact skin is an effective barrier to paraquatabsorption
: irritation, blistering, burns
: severe corneal/conjunctiva inflammation
• Ingestion
: acute toxicity and rapidly fatal systemic poisoning
Route of exposure
-
8/16/2019 Organophosphate Paraquat
25/38
Paraquat Lung
O2 O2.
OH.
Lipidperoxidation
Type I and II pneumocyte cell death & alveolitis
Lung fibrosis
GSH* GSSG**
Mechanism of toxicity
*GSH : Glutathione **GSSG : Glutathione disulfide
-
8/16/2019 Organophosphate Paraquat
26/38
• H5, )*4# Paraquat 7E0 $.8&50 ' UL 0 8V'9!, *!"F$*$+F$7@"9# 7#I DF)@$* Paraquat (" DE$9G$!(0 F)G5$/(, D'.8@6!"9$(A$JH0 F$7@"9#U2!F9L M/0 '9 73I DF5/%'$!78Q#34-EF)2$+#" C
• P$9J# 24 B,D'O!)&+* @6!"F$*$+($)+611($)7/4#F$H$+2M'#G0 # 7#I DF)@$*^(=4 _ +6%$97%IF)EF) Paraquat
• &U51'!&/)J#8$*&5654 C# 78Q# patch E$'%5>!&U5 • J#+$9(" D+>#&+)F$@31 Ruptured Esophagus
• 8'/(0 F) F$7@"9# (0 F)72"9
Clinical Presentation
-
8/16/2019 Organophosphate Paraquat
27/38
• P$9J# 1-3 ', #GMF!$@6!"F$*$+($) Systemic
• Renal failure Oliguria , Uremia Acute tubular necrosis
• Liver failure Elevated SGOT,SGPT
Hepatocellular damage • Respiratory failure
Pulmonary hemorrhage Pulmonary edema
Pulmonary fibrosis
Clinical Presentation
-
8/16/2019 Organophosphate Paraquat
28/38
• Mild or subacute poisoning:
< 30 mg/kg- Asymptomatic or vomiting and diarrhoea.- Renal and hepatic lesions are minimal or absent.- An initial decrease of the pulmonary diffusion
capacity may be present.
• Complete recovery would be expected.
Clinical Presentation
-
8/16/2019 Organophosphate Paraquat
29/38
• Moderate to severe acute poisoning:
31-50 mg /kg- Immediate: vomiting.- Hours: diarrhea, abdominal pain, mouth and throatulceration.
- One to four days: renal failure, hepatic impairment,hypotension and tachycardia.- One to two weeks: cough, hemoptysis, pleuraleffusion, pulmonary fibrosis with deteriorating lung
function.
• Survival is possible, but in the majority of cases deathoccurs within 2 - 3 weeks from pulmonary failure.
Clinical Presentation
-
8/16/2019 Organophosphate Paraquat
30/38
• Fulminant:
>40 - 55 mg/kg mg/kg- Immediate: vomiting#- Hours to days: diarrhoea, abdominal pain, renal andhepatic failure, gastrointestinal ulceration,
pancreatitis, toxic myocarditis, hypotension, coma,convulsions.
• Death from cardiogenic shock and multi-organ failureoccurs within 1-4 days
Clinical Presentation
-
8/16/2019 Organophosphate Paraquat
31/38
• Biomarker
1.Biomarker of exposure
1.1 Paraquat Spot Test : Urine , Gastric content • 1. #A$8K22$'6H+IFEF)7H5'(" D/L/@$**+673$68+4!$S 10 ]"]" J2M5)J#H5F/(/5F)
• 2. 7G4!/M$) 7BM# sodium hydroxide 5).8@# pH 2L)*'M$ 9 (F$@JB0 sodiumbicarbonate 8+6!$S 2.5 - 5 ]"]" &(#./0 )
• 3. 7G4! sodium dithionite E#$/7(M$85$9B0 F#B$5)J#G, 'F9M$) 7E9M$71$` • 4. #A$H5F/(/5F).82MF)/L*, 13I C #2"E$' Z0 $!"2"#C A$7)4#H+IF2"7E"9'7*4/EW C # &2/)'M$!"3$+$%'F(F9L M J#G, 'F9M$)#, C # &5678Q#*$+9I#9, #*$+'4#4@T, 9O+% H$*J#G, 'F9M$)!"3$+$%'F(F9L M J#%'$!7E0 !E0 #2L) 2"(" D7*4/EW C #F$@@6*5$978Q#2"/A$ JH0 G+'@]C A$F"*%+, C ) O/97@IF@$)G, 'F9M$)5)
1.2 Paraquat level : Plasma , Urine
Laboratory
-
8/16/2019 Organophosphate Paraquat
32/38
H#M'934-'4(9$ +3.+$!$=41/"
-
8/16/2019 Organophosphate Paraquat
33/38
• Supportive treatment
• Primary assessment • Ensure Airway, Breathing and Circulation are intact
• Do not give supplemental oxygen unless serious
hypoxia is present.• Rehydrate the patient to optimise renal clearance of
paraquat.
• Control vomiting
• Ondansetron 8mg by slow IV injection or IV infusion over15 mins
Treatment
-
8/16/2019 Organophosphate Paraquat
34/38
• Specific treatment
• Skin Decontamination
• GI Decontamination • Gastric lavage
• Prevent absorption
• Fuller’s Earth 150 gm + Water 1 L
• 7.5% Bentonite 100-150 gm
• Activated Charcoal 100-150 gm
• Milk of Magnesia 30 cc q 4-6 hr
• Increase elimination • Hemodialysis / Hemoperfusion
Treatment
-
8/16/2019 Organophosphate Paraquat
35/38
• Specific treatment
• Modification of tissue toxicities • Modulate inflammatory responses
• Cyclophosphamide 5mg/kg/day IV divided to every 8 hr
• Dexamethazone 10 mg IV q 8 hr
• Chlorpheniramine 4 mg 1 tab po qid
• Prevent oxidation • Vit C (500mg/amp) 6 g/day IV
• Vit E (400 i.u./ tab) 2 tabs qid
• N-acetylcysteine (300mg/amp) 50mg/kg divided to every 8 hr
Treatment
-
8/16/2019 Organophosphate Paraquat
36/38
• J#8K@@>1, #($):L#9? 34-'4(9$ +3.+$!$=41/" #A$ regimen (" D JB0 *$++, *-$34-@$*3$+$%'F(/, )#" C
• Cyclophosphamide 5 mg/kg/day ($)H5F/75IF//A$ &1M)JH0 (>*
8 B, D'O!)
• Dexamethasone 10 mg IV (>* 8 B, D'O!)
• Vitamine C (500 mg/amp) 6 gm/day ($)H5F/75IF//A$
• Vitamine E (400 IU/tab) 2 tabs ', #564 %+, C )
Treatment
-
8/16/2019 Organophosphate Paraquat
37/38
-
8/16/2019 Organophosphate Paraquat
38/38
• Standing order for paraquat.docx
'($)*$+/L&5+, *-$
http://localhost/var/www/apps/conversion/tmp/scratch_5///ppt/slides/Standing%20order%20for%20paraquat.docxhttp://localhost/var/www/apps/conversion/tmp/scratch_5///ppt/slides/Standing%20order%20for%20paraquat.docx